Purchase Order 75N95022P00371
Award Date 7/20/22
Potential Completion Date 7/24/23
Potential Value $110K
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Malvern, PA 19355, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
1
Legislative Mandate
Service Contract Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $118,430.00 firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for testing 15 novel small molecule compounds using Reaction Biology's proprietary Kinase HotSpot assay platform. This work supports translational research efforts across the NIH. The purchase order was...
- Reaction Biology Corporation was awarded a $16,480.80 firm fixed price purchase order by the National Institutes of Health's National Center for Advancing Translational Sciences to test 35 novel small molecule compounds for inhibition of three wild-type kinase enzymes. Under the contract, Reaction Biology will utilize its Kinase HotSpot assay platform to test each compound at 10 different doses and provide one comprehensive report detailing results against the three kinases. The testing services...
- Reaction Biology Corporation has been awarded a $100,560 firm fixed price purchase order by the Department of Health and Human Services' National Institutes of Health National Center for Advancing Translational Sciences to provide GAMMA 33P ATP Kinase Assay and NanoBRET Kinase Assay testing services. As a prime contractor, Reaction Biology will utilize its Kinase HotSpot and Methyltransferase HotSpot platforms to test libraries of novel compounds against panels of wild-type kinases and...
- This is a firm fixed price purchase order awarded by the Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse to Reaction Biology Corporation, a small disadvantaged business contractor. The contract is for the testing of compounds for inhibition of 370 wild-type kinase enzymes, with a potential value of $166,500.00 and a completion date of December 6, 2022. Reaction Biology has previously provided kinase inhibition testing, cancer cell line...
- This $125,600.00 firm fixed-price purchase order was awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business, to conduct testing of novel small molecule compounds for kinase inhibition. The contract does not have a set-aside designation. The work involves screening 300 compounds against 3 wild-type kinases and 10 compounds against a panel of 50 wild-type kinases using...
- This is a firm fixed-price purchase order awarded by the National Institutes of Health's National Center for Advancing Translational Sciences to Reaction Biology Corporation, a self-certified small disadvantaged business. The $21,027.68 contract is for the testing of 2 compounds against a selected kinase panel in a biochemical gamma 33P-ATP kinase assay. Reaction Biology specializes in enzyme activity assays and has previously provided kinase inhibition testing, cancer cell line screening, and...
- This is a firm fixed-price purchase order awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute on Drug Abuse to Reaction Biology Corporation, a self-certified small disadvantaged business. The $143,260.00 contract is for kinase screening services, with Reaction Biology testing 377 wild-type kinases against 10 compounds. The award stems from a non-competitive solicitation issued by the NIH's National Center for Advancing Translational...
- The National Center for Advancing Translational Sciences (NCATS), a civilian agency within the U.S. Department of Health and Human Services, awarded a firm-fixed-price purchase order contract worth $18,028.80 to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract, which does not have a set-aside designation, was awarded on June 5, 2019, with a completion date of December 13, 2019. Reaction Biology Corporation, a drug discovery contract research organization,...
- This $19,833.68 firm fixed-price purchase order contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for profiling 10 BTK (Bruton's tyrosine kinase) inhibitors against a panel of 20 kinases. Reaction Biology is a drug discovery contract research organization that specializes in enzyme...
- This is a $19,840.00 firm-fixed price purchase order awarded by the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), to Reaction Biology Corporation, a self-certified small disadvantaged business. The contract is for biochemical kinase assays on 160 compounds to determine their inhibitory activity against the kinases LATS1, LATS2, and AKT, which will inform the development of potential anti-cancer agents. This award was a...